(Fluconazole TABLET, SUSPENSION)
(1) Hepatic injury: DIFLUCAN should be administered with caution to patients with liver dysfunction. DIFLUCAN has been associated with rare cases of serious hepatic toxicity, including fatalities primarily in patients with serious underlying medical conditions. In cases of DIFLUCAN-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex, or age of the patient has been observed. DIFLUCAN hepatotoxicity has usually, but not always, been reversible on discontinuation of therapy. Patients who develop abnormal liver function tests during DIFLUCAN therapy should be monitored for the development of more severe hepatic injury. DIFLUCAN should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to DIFLUCAN.
(2) Anaphylaxis: In rare cases, anaphylaxis has been reported.
(3) Dermatologic: Exfoliative skin disorders during treatment with DIFLUCAN have been reported. Fatal outcomes have been reported in patients with serious underlying diseases. Patients with deep seated fungal infections who develop rashes during treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions progress. Fluconazole should be discontinued in patients treated for superficial fungal infection who develop a rash that may be attributed to fluconazole.
(4) Potential for fetal harm: There are no adequate and well-controlled clinical trials of DIFLUCAN in pregnant women. Case reports describe a pattern of distinct congenital anomalies in infants exposed in utero to high dose maternal fluconazole (400 to 800 mg/day) during most or all of the first trimester. These reported anomalies are similar to those seen in animal studies. If DIFLUCAN is used during pregnancy or if the patient becomes pregnant while taking the drug, the patient should be informed of the potential hazard to the fetus. Effective contraceptive measures should be considered in women of child-bearing potential who are being treated with DIFLUCAN 400 to 800 mg/day and should continue throughout the treatment period and for approximately 1 week (5 to 6 half-lives) after the final dose. Epidemiological studies suggest a potential risk of spontaneous abortion and congenital abnormalities in infants whose mothers were treated with 150 mg of fluconazole as a single or repeated dose in the first trimester, but these epidemiological studies have limitations and these findings have not been confirmed in controlled clinical trials. (See PRECAUTIONS: Pregnancy.)
PATIENT INFORMATION | ||||
This leaflet contains important information about DIFLUCAN. It is not meant to take the place of your healthcare provider's instructions. Read this information carefully before you take DIFLUCAN. Ask your healthcare provider if you do not understand any of this information or if you want to know more about DIFLUCAN. | ||||
What is DIFLUCAN? | ||||
What is a vaginal yeast infection?
| ||||
Do not take DIFLUCAN if you.
| ||||
Before you take DIFLUCAN, tell your healthcare provider about all of your medical conditions, if you:
Before you start taking DIFLUCAN, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take:
Since there are many brand names for these medicines, check with your healthcare provider or pharmacist if you have any questions. | ||||
How should I take DIFLUCAN?
| ||||
What should I avoid while taking DIFLUCAN? | ||||
What are the possible side effects of DIFLUCAN?
| ||||
|
|
| ||
| ||||
|
|
| ||
The most common side effects of DIFLUCAN include: | ||||
|
|
| ||
Other side effects include:
| ||||
|
|
| ||
|
|
| ||
|
| |||
| ||||
These are not all the possible side effects of DIFLUCAN. | ||||
How should I store DIFLUCAN? | ||||
General information about the safe and effective use of DIFLUCAN. | ||||
What are the ingredients in DIFLUCAN? | ||||
![]()
| ||||
This Patient Information has been approved by the U.S. Food and Drug Administration | Revised: 3/2025 | |||
LAB-0380-16.0
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.